Myeloid Cell Nuclear Differentiation Antigen (MNDA) Positivity in Primary Follicles: Potential Pitfall in the Differential Diagnosis With Marginal Zone Lymphoma.
Adolescent
Adult
Aged
Aged, 80 and over
Antigens, Differentiation, Myelomonocytic
/ metabolism
Biomarkers, Tumor
/ metabolism
Cell Nucleus
/ metabolism
Diagnosis, Differential
Female
Humans
Immunohistochemistry
Lymphoma, B-Cell, Marginal Zone
/ diagnosis
Lymphoma, Follicular
/ diagnosis
Middle Aged
Myeloid Cells
/ metabolism
Myelopoiesis
Transcription Factors
/ metabolism
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
Historique:
pubmed:
15
1
2019
medline:
11
5
2021
entrez:
15
1
2019
Statut:
ppublish
Résumé
Myeloid cell nuclear differentiation antigen (MNDA) is an immunohistochemical marker that is used to distinguish marginal zone lymphomas (MZLs) from other small B-cell lymphomas. An index case that showed MNDA staining in primary follicles prompted the current study to evaluate whether MNDA expression is widespread in primary follicles and to address whether it poses a potential diagnostic pitfall. Of the 15 cases with primary follicles identified by a search of the laboratory information system, 7 had positive MNDA staining. In all cases, there was weak nuclear staining similar to what is typical of MNDA staining in MZLs. All cases showed intense nuclear signal in myeloid lineage cells such as neutrophils, which served as positive internal controls. The histologic and cytologic features of primary follicles and MZLs showed overlapping features, particularly in small biopsies. Our results indicate that weak nuclear MNDA staining can act as a potential pitfall in the evaluation of small B-cell lymphomas. Correlation with other immunohistochemical markers that are useful in the workup of small B-cell lymphomas, as well as those that outline immunoarchitectural features of lymphoid follicles, is suggested when both entities are part of the differential diagnosis. Our results underscore the need for caution in the interpretation of weak nuclear MNDA staining in the evaluation of small B-cell lymphomas.
Identifiants
pubmed: 30640752
doi: 10.1097/PAI.0000000000000738
pii: 00129039-202005000-00008
doi:
Substances chimiques
Antigens, Differentiation, Myelomonocytic
0
Biomarkers, Tumor
0
MNDA protein, human
0
Transcription Factors
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
384-388Références
Johnstone RW, Trapani JA. Transcription and growth regulatory functions of the HIN-200 family of proteins. Mol Cell Biol. 1999;19:5833–5838.
Liu T, Rojas A, Ye Y, et al. Homology modeling provides insights into the binding mode of the PAAD/DAPIN/pyrin domain, a fourth member of the CARD/DD/DED domain family. Protein Sci. 2003;12:1872–1881.
Reed JC, Doctor K, Rojas A, et al. Comparative analysis of apoptosis and inflammation genes of mice and humans. Genome Res. 2003;13:1376–1388.
Kanellis G, Roncador G, Arribas A, et al. Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia. 2009;23:1847–1857.
Joshi AD, Hegde GV, Dickinson JD, et al. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2007;13:5295–5304.
Briggs R, Dworkin L, Briggs J, et al. Interferon alpha selectively affects expression of the human myeloid cell nuclear differentiation antigen in late stage cells in the monocytic but not the granulocytic lineage. J Cell Biochem. 1994;54:198–206.
Geng Y, Choubey D. Differential induction of the 200-family proteins in Daudi Burkitt’s lymphoma cells by interferon-alpha. J Biol Regul Homeost Agents. 2000;14:263–268.
Miranda RN, Briggs RC, Shults K, et al. Immunocytochemical analysis of MNDA in tissue sections and sorted normal bone marrow cells documents expression only in maturing normal and neoplastic myelomonocytic cells and a subset of normal and neoplastic B lymphocytes. Hum Pathol. 1999;30:1040–1049.
Metcalf R, Monabati A, Vyas M, et al. Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma. Human Pathol. 2014;45:1730–1736.
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon: IARC; 2017.
Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2012;30:429–457.
Ruuls SR, Hoek RM, Ngo VN, et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity. 2001;15:533–543.
Kasajima-Akatsuka N, Maeda K. Development, maturation and subsequent activation of follicular dendritic cells (FDC): immunohistochemical observation of human fetal and adult lymph nodes. Histochem Cell Biol. 2006;126:261–273.
Zhang X, Aguilera N. New Immunohistochemistry for B-Cell Lymphoma and Hodgkin lymphoma. Arch Pathol Lab Med. 2014;138:1666–1672.
Traverse-Glehen A, Baseggio L, et al. Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification. Curr Opin Oncol. 2011;23:441–448.
Naresh KN. Nodal marginal zone B-cell lymphoma with prominent follicular colonization—difficulties in diagnosis: a study of 15 cases. Histopathology. 2008;52:331–339.
Wang E, West D, Kulbacki E. An unusual nodal marginal zone lymphoma with bright CD10 expression: a potential diagnostic pitfall. Am J Hematol. 2010;85:546–548.
Van den Brand M, Mathijssen JJM, Garcia-Garcia M, et al. Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma–combined performance of multiple markers. Haematologica. 2015;100:358–360.